GLP-2 drug class dominates the leading markets in North America and Europe
The global short bowel syndrome market is segmented on the basis of drug class and geography. On the basis of drug class, the market is divided into GLP-2, growth hormone, glutamine and others.
Increasing prescription of Gattex Therapy for Short Bowel Syndrome in North America creates a highly lucrative prospect for growth
Regional segmentation of the short bowel syndrome market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest share in global market, mainly due to presence of major players and early adoption of advanced medical technologies in countries such as the U.S. and Canada. According to National Institute of Diabetes and Digestive and Kidney Disease, in 2008, there were more than 2,000 intestinal transplantations performed in the U.S., out of which 75% population was of the age group of 18-20 years. These numbers are expected to increase year on year, which would inadvertently fuel growth of the short bowel syndrome market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients